Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Crown Bioscience Announces Research Collaboration with the NRCMM

Published: Saturday, May 10, 2014
Last Updated: Saturday, May 10, 2014
Bookmark and Share
New collaboration aims to develop disease-specific experimental models for translational medical research.

Crown Bioscience, Inc. has announced that an agreement has been reached with the National Resource Center for Mutant Mice (NRCMM), in Nanjing, Jiangsu Province, China.

The strategic partnership will focus on developing new experimental cancer models to advance translational medical research and the treatment of cancers.

The immediate focus of the research collaboration will be to build new experimental models for cancer research leveraging the proprietary technologies of both companies.

The collaboration is expected to significantly expand the research capabilities of both organizations in translational oncology and will thus benefit the global research community fighting cancers.

Crown Bioscience is the premier service provider of translational oncology and metabolic diseases platforms providing focused disease models. It has one of the largest and most advanced translational oncology platforms featuring fully annotated collections of proprietary patient derived xenograft (PDX) models (>1000).

NRCMM is a leading research organization specialized in genetically engineered mutant mouse (GEMM), with vast resources, including a large collection of GEMMs, many of which mimic human cancers. Both parties have complimentary expertise and experience in Oncology and GEMMs, and therefore the established joint effort will have great synergy in creating new translational oncology platforms based on GEMMs.

The collaboration will offer significantly expanded new mouse cancer and leukemia models based on GEMM as well as new human xenografts, in addition to the current PDX and CDX platforms (Cell line Derived Xenograft) at Crown and the current GEMMs at NRCMM.

In particular, novel mouse strains with various humanizations could be particularly powerful tools for immune-oncology research and immunotherapy drug evaluations.

After the signing of the agreement, Dr. Jean-Pierre Wery, Crown’s President, commented: “Crown plays a leading role in providing cutting-edge translational platforms and cost effective drug development solutions for almost all top pharmaceutical companies worldwide. Crown is very happy to partner with NRCMM, the leading research institute for genetically engineered animals in China. This partnership will offer world-class translational oncology services, and ultimately benefit cancer patients around the world. This collaboration will further strengthen Crown’s leading position as the oncology translational medicine partner for drug discovery organizations worldwide”.

Dr. Gao, Director of NRCMM, also commented: “As the largest government-funded research institute focusing on genetically engineered mice in China, NRCMM is an important member of the global community of GEMM research. Working together with a world leading translational oncology service provider, such as Crown, the combined expertise of Crown in oncology and our GEMM can certainly offer great GEMM-based oncology platforms to our partners in China and around the world. We are certainly excited about this opportunity.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Crown Bioscience Brings Top Scientists Together
Experts to discuss best approaches to advance translational oncology.
Saturday, October 03, 2015
Crown Bioscience Announces U.S. Expansion
New service center will allow the expansion of new immunotherapy experimental platforms to advance translational medical research and the treatment of cancers.
Saturday, October 25, 2014
Crown Reveals Strategy for Combined Drug-IR Therapy to Overcome Resistance
Novel strategies for combining drug therapy with irradiation to deliver new hope for overcoming resistance in the clinic.
Saturday, June 21, 2014
Crown Bioscience Receives $26.55M Series D Funding
Investment will fund rapid expansion in translational platform technologies for oncology and metabolic diseases.
Monday, May 12, 2014
SIMM and Crown Bioscience Reach Landmark Agreement
Agreement to develop world-leading mouse clinical center and largest annotated PDX and translational oncology platform.
Friday, November 29, 2013
Crown Bioscience Enter Into a Business Collaboration with Xstrahl Ltd
Development of radiation models of cancer will enable the discovery of more effective oncology therapies.
Tuesday, October 15, 2013
Scientific News
Researchers Develop Classification Model for Cancers Caused by KRAS
Most frequently mutated cancer gene help oncologists choose more effective cancer therapies.
Tolerant Immune System Increases Cancer Risk
Researchers have found that individuals with high immunoCRIT ratios may have an increased risk of developing certain cancers.
Developing a Gel that Mimics Human Breast for Cancer Research
Scientists at the Universities of Manchester and Nottingham have been funded to develop a gel that will match many of the biological structures of human breast tissue, to advance cancer research and reduce animal testing.
New Gene Therapy for Vision Loss From a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
Predictive Model for Breast Cancer Progression
Biomedical engineers have demonstrated a proof-of-principle technique that could give women and their oncologists more personalized information to help them choose options for treating breast cancer.
Specific Variations in RNA Splicing Linked to Breast Cancer
Researchers have identified cellular changes that may play a role in converting normal breast cells into tumors. Targeting these changes could potentially lead to therapies for some forms of breast cancer.
Gene Expression: A Snapshot of Stem Cell Development
New genes found that regulate development of stem cells.
Assessing Cancer Patient Survival and Drug Sensitivity
RNA editing events another way to investigate biomarkers and therapy targets.
Editing Genes to Create HIV Killers
Seattle scientists have managed to genetically transform human cells in the lab from HIV targets to HIV killers, and the technique could have implications for cancer and other diseases.
Researchers Disguise Drugs As Platelets to Target Cancer
Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient’s own platelets.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos